Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -46.26% is 18% above its 5-year average of -56.22%, near the high end of its 5-year range (-79.34%–-33.32%).
16.29% above its 12-month average of -55.26%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -15.75%.
RETURN ON ASSETS (ROA)
-46.26%
RETURN ON ASSETS (ROA) AVG TTM
-55.26%
RETURN ON ASSETS (ROA) AVG 3Y
-67.06%
RETURN ON ASSETS (ROA) AVG 5Y
-56.22%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+16.29%
CURRENT VS 3Y AVG
+31.02%
CURRENT VS 5Y AVG
+17.72%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.48%
median of 784 covered companies
CURRENT VS SECTOR MEDIAN
-46.97%
vs the sector median at left
Milestone Pharmaceuticals Inc.
Market Cap
$97.61M
Return on Assets (ROA)
-46.26%
TTM Avg
-55.26%
3Y Avg
-67.06%
5Y Avg
-56.22%
Market Cap
$97.49M
Return on Assets (ROA)
-65.25%
TTM Avg
-70.13%
3Y Avg
-63.89%
5Y Avg
-46.24%
Market Cap
$99.61M
Return on Assets (ROA)
-206.78%
TTM Avg
-134.13%
3Y Avg
-143.93%
5Y Avg
-119.05%
Market Cap
$97.00M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$102.25M
Return on Assets (ROA)
-32.73%
TTM Avg
-70.83%
3Y Avg
-106.23%
5Y Avg
-81.00%
Market Cap
$102.67M
Return on Assets (ROA)
7.36%
TTM Avg
-1.10%
3Y Avg
-3.18%
5Y Avg
2.66%
Market Cap
$91.30M
Return on Assets (ROA)
-88.24%
TTM Avg
-139.34%
3Y Avg
-100.15%
5Y Avg
-71.92%
Market Cap
$93.48M
Return on Assets (ROA)
-1.90%
TTM Avg
1.32%
3Y Avg
1.93%
5Y Avg
1.93%
Market Cap
$104.68M
Return on Assets (ROA)
-57.98%
TTM Avg
-386.38%
3Y Avg
-312.00%
5Y Avg
-312.00%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | $97.61M | -46.26% | -55.26% | -67.06% | -56.22% |
| Korro Bio, Inc. (KRRO)vs › | $97.49M | -65.25% | -70.13% | -63.89% | -46.24% |
| PolyPid Ltd. (PYPD)vs › | $99.61M | -206.78% | -134.13% | -143.93% | -119.05% |
| Conexeu Sciences Inc. (CNXU)vs › | $97.00M | N/A | N/A | N/A | N/A |
| OnKure Therapeutics, Inc. (OKUR)vs › | $102.25M | -32.73% | -70.83% | -106.23% | -81.00% |
| The Joint Corp. (JYNT)vs › | $102.67M | 7.36% | -1.10% | -3.18% | 2.66% |
| Biomea Fusion, Inc. (BMEA)vs › | $91.30M | -88.24% | -139.34% | -100.15% | -71.92% |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $93.48M | -1.90% | 1.32% | 1.93% | 1.93% |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $104.68M | -57.98% | -386.38% | -312.00% | -312.00% |
| Equillium, Inc. (EQ)vs › | $90.73M | -30.70% | -50.88% | -51.94% | -48.05% |
ROA
-46.3%
ROE
-461.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -55.53% |
| 2024-12-31 | -54.99% |
| 2023-12-31 | -79.34% |
| 2022-12-31 | -78.39% |
| 2021-12-31 | -35.76% |
| 2020-12-31 | -33.32% |
| 2019-12-31 | -44.75% |
| 2018-12-31 | -26.32% |
| 2017-12-31 | -29.31% |
